Allworth Financial LP Cerevel Therapeutics Holdings, Inc. Transaction History

Allworth Financial LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	BUY	$38.96 - $42.75 $1,831 - $2,009	47 Added 73.44%	111 $4,000
Q4 2023 Jan 24, 2024	BUY	$20.27 - $42.44 $385 - $806	19 Added 42.22%	64 $2,000
Q3 2023 Oct 31, 2023	BUY	$20.26 - $31.91 $911 - $1,435	45 New	45 $0
Q4 2022 Jan 13, 2023	BUY	$25.35 - $31.96 $152 - $191	6 New	6 $0

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

Stay updated on Allworth Financial LP with notifications on news.